Going back to class I: MHC and immunotherapies for childhood cancerKellie B. Haworth, Timothy P. Cripe, Jennifer L. Leddon et al.|Pediatric Blood & Cancer|2014Cited by 86
Rescue of the genetically engineered Cul4b mutant mouse as a potential model for human X-linked mental retardationChun‐Yu Chen, Ming‐Shian Tsai, I‐Shing Yu et al.|Human Molecular Genetics|2012Cited by 58
Myelolytic Treatments Enhance Oncolytic Herpes Virotherapy in Models of Ewing Sarcoma by Modulating the Immune MicroenvironmentNicholas Denton, Timothy P. Cripe, Chun‐Yu Chen et al.|Molecular Therapy — Oncolytics|2018Cited by 56
Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivityJennifer L. Leddon, Timothy P. Cripe, Amy C. Gross et al.|Molecular Therapy — Oncolytics|2014Cited by 44
Pediatric cancer gone viral. Part I: strategies for utilizing oncolytic herpes simplex virus-1 in childrenTimothy P. Cripe, Gregory K. Friedman, Chun‐Yu Chen et al.|Molecular Therapy — Oncolytics|2015Cited by 22